Articles by Sarah L. Sammons
77 Updated Efficacy of Mutant-Selective PI3Kα Inhibitor Zovegalisib (RLY-2608) in Combination With Fulvestrant in Patients With PIK3CA-Mutant HR+/HER2– Advanced Breast Cancer: ReDiscover Trial
BySarah L. Sammons,Cristina Saura,Antoine Italiano,Alison Schram, MD,Pablo Tolosa,Anne F. Schott, MD,Á. Guerrero-Zotano,Santiago Ponce-Aix,Rita Nanda, MD,Kari B. Wisinski, MD,Jennifer Segar,Mei Wei,Jia (Jenny) Liu,Alexander Spira, MD, PhD, FACP, FASCO,Julia E. McGuinness, MD,Jordi Rodón,Cynthia X. Ma, MD, PhD,Milana Bergamino,Giuseppe Curigliano,Andreas Varkaris Zovegalisib plus fulvestrant demonstrated an objective response rate of 38.7% and a median progression-free survival of 10.3 months in PIK3CA-mutant HR+/HER2– advanced breast cancer in the ReDiscover trial.
TIP125 ReDiscover-2, a Phase 3 Study of Zovegalisib (RLY-2608) + Fulvestrant Versus Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-Mutant HR+/ HER2- Breast Cancer Following Recurrence or Progression on or After Treatment With a CDK4/6 Inhibitor (Trial in Progress)
ByHope S. Rugo, MD,Cristina Saura,Komal Jhaveri,Carlos Barrios,Sherene Loi, MD, PhD,Frederik Marme,Francois Clement Bidard,Yeon Hee Park,Peter Schmid, MD,Sarah L. Sammons,Giuseppe Curigliano 
16 Open-Label, Randomized, Multicenter, Phase 3, ELAINE 3 Study of the Efficacy and Safety of Lasofoxifene Plus Abemaciclib for Treating ER+/HER2–, Locally Advanced or Metastatic Breast Cancer With an ESR1 Mutation
ByMatthew P. Goetz, MD,Seth A. Wander,Thomas Bachelot,Gerald Batist,Javier Cortés, MD,Massimo Cristofanilli, MD,Giuseppe Curigliano,Alexandre de Nonneville,Einav Nili Gal-Yam,Komal Jhaveri,Cynthia X. Ma, MD, PhD,Heather A. Parsons, MD, MPH,Hope S. Rugo, MD,Sarah L. Sammons,Daniel G. Stover,Chris Twelves, MD, FRCP,Aditya Bardia, MD, MPH, FASCO,Paul V. Plourde,David J. Portman,Senthil Damodaran
